@strangelogic Diagnosis of NAFLD/NASH in fact is quite difficult and in some cases requires invasive biopsies. I believe EMV will attempt to produce a product that can detect irregularities/differences between healthy/fatty/fiborous liver tissue and then Doctors can make decisions based on that information. Cheap and non-invasive is the key here. All IMO of course. 1 in 4 people worldwide have this disease.
Ann: Investor Presentation, page-6
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EMV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.93 |
Change
0.040(2.12%) |
Mkt cap ! $174.4M | |||
| Open | High | Low | Value | Volume |
| $1.91 | $1.95 | $1.91 | $140.5K | 72.96K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2067 | $1.90 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.93 | 4701 | 1 |
View Market Depth
| Last trade - 16.10pm 25/11/2024 (20 minute delay) ? |
| EMV (ASX) Chart |
